🇮🇳 India Stock Screener ← Switch market ★ Elite Club ⚡ HerAI

AMANTA HEALTHCARE LIMITED AMANTA NSEPHARMA

Healthcare · Drug Manufacturers - Specialty & Generic · India
https://www.amanta.co.in
Company Profile ↓
₹168.64
+18.19% 1Y
Mkt Cap₹654.82 Cr
P/E38.95
P/B2.74
52W High₹186.47
52W Low₹95.03
Book Value₹56.71
EPS (TTM)₹4.33

Company Overview

Amanta Healthcare Limited operates as a pharmaceutical company engaged in developing, manufacturing and marketing a diverse range of sterile liquid products and parenteral products in Africa, Latin America, the United Kingdom, and internationally. The company manufactures its products in three product group segments Large Volume Parenteral, Nipple Head (Single Port), SteriPort (Two Ports), and Small Volume Parenteral. Additionally, it manufactures medical devices and fluid therapy - (IV Fluid), formulations, diluents, ophthalmic, respiratory care and irrigation solutions in therapeutic segment and products, such as irrigation, first-aid solution, and eye lubricants in medical device segment. It also offers a wide range of closure systems, such as nipple head, twist-off, leur-lock, and screw types and container fill-volume ranging from 2ml to 1000 ml. Its markets its products through three strategic business units including national sales, international sales, and product partnering with various foreign and Indian pharmaceutical companies. Amanta Healthcare Limited was formerly known as Marck Biosciences Limited and changed its name to Amanta Healthcare Limited in June 2014. Amanta Healthcare Limited was incorporated in 1994 and is headquartered in Ahmedabad, India.

Why Investors Should Care

Consistent Profit Growth

Net profit has compounded at 268.3% per year over the last five years.

Reasonable Valuation

Trades at a P/E of 39.0, below the sector median of 39.7.

Recent Developments

  • Mar 2026 Revenue of ₹287.68 Cr (+4.7% YoY); net profit ₹14.88 Cr.
  • Trailing 12 Months Year-on-year growth — revenue +4.7%, earnings +41.7%.
  • 5-Year Trend Long-term compounding — revenue CAGR 3.8%, profit CAGR 268.3%.

Growth & Price Performance

Compounded Sales Growth

5 Years:3.76%
1 Year:4.72%

Compounded Profit Growth

5 Years:268.26%
1 Year:41.66%

Stock Price Performance

1 Year:+18.19%
6 Months:+54.99%
3 Months:+29.88%
1 Month:+12.22%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bullish
52-Week Range 81% of range
₹95.03 ₹186.47
Trend Signals
  • Price vs 50-DMAAbove
  • Price vs 200-DMAAbove
  • RSI (14)56.90 · Neutral
Price Performance
1M+12.22%
3M+29.88%
6M+54.99%
1Y+18.19%
Valuation vs Sector

P/E of 38.95 is below the sector median of 39.70 — relatively cheaper than peers.

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

NSE TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • Profit CAGR of 268.3% over 5 years.
  • In a confirmed uptrend (50-DMA above 200-DMA).

CONS

No notable concerns flagged.

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
38.95
Industry PE
39.70
Forward P/E est.
27.50
PEG Ratio
-
Book Value
₹56.71
Price to Book
2.74
P/S
2.37
EV/EBITDA
12.82
Dividend Yield
0.00%

Growth (CAGR)

Revenue 5Y
3.76%
Profit 5Y
268.26%
Revenue (YoY)
4.72%
Earnings (YoY)
41.66%

Profitability & Returns

ROCE
10.04%
ROE
6.75%
ROA
2.67%
Profit Margin
5.17%
Op Margin
14.30%
Gross Margin
66.40%
EPS (Latest Qtr)
₹1.61
EPS (TTM)
₹4.33

Balance Sheet & Liquidity

Debt/Equity
1.11
Quick Ratio
1.10
Current Ratio
1.69
Debt
₹244.44 Cr
Total Assets
₹557.98 Cr
Current Assets
₹238.53 Cr
Working Capital
₹97.47 Cr

Ownership

Promoter Holding
68.50%
Chg in Prom Hold
0.08%
FII / Inst Holding
6.92%
Chg in FII Hold
-

Financial Snapshot

Enterprise Value
₹654.82 Cr
Total Revenue (TTM)
₹287.68 Cr
EBITDA
₹60.60 Cr
Free Cash Flow
₹-31.74 Cr
Operating Cash Flow
₹48.45 Cr
Shares Outstanding
₹3.88 Cr
Gross Margin
66.40%
Payout Ratio
0.00%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP ₹P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 AMANTA AMANTA HEALTHCARE LIMITED NSEPHARMA 168.64 38.95 ₹654.82 Cr 0.00% 10.04% 6.75% 3.76% 268.26%
2 SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA 1,948.80 40.77 ₹4.68 L Cr 0.83% 17.94% 13.74% 10.39% 10.65%
3 DIVISLAB Divi's Laboratories Limited NSEPHARMA 7,315.50 75.61 ₹1.94 L Cr 0.44% 18.96% 15.32% 11.27% 12.08%
4 TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA 4,952.20 87.70 ₹1.68 L Cr 0.78% 9.05% 25.79% 13.27% 20.22%
5 APOLLOHOSP Apollo Hospitals Enterprise Limited NIFTY50NSEAIPHARMA 8,981.00 66.51 ₹1.29 L Cr 0.23% 19.79% 20.48% 15.33% 33.34%
6 CIPLA Cipla Limited NIFTY50NSEAIPHARMA 1,440.10 22.07 ₹1.16 L Cr 0.90% 14.86% 11.27% 7.23% 11.45%
7 ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA 1,137.40 22.71 ₹1.14 L Cr 0.09% 19.04% 18.59% 16.55% 36.99%
8 LUPIN Lupin Limited NIFTY_MIDNSEPHARMA 2,494.30 21.42 ₹1.14 L Cr 0.72% 28.42% 23.76% 19.10% 131.46%
9 MAXHEALTH Max Healthcare Institute Limited NSEAIPHARMA 1,099.00 99.82 ₹1.07 L Cr 0.18% 12.57% 13.42% 22.37% 9.34%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in INR.

Metric Dec 2024Mar 2025Sep 2025Dec 2025Mar 2026
Revenue 67.81 Cr72.06 Cr70.89 Cr74.49 Cr76.99 Cr
Cost of Revenue 21.60 Cr24.47 Cr23.37 Cr26.29 Cr28.87 Cr
Gross Profit 46.21 Cr47.59 Cr47.52 Cr48.20 Cr48.13 Cr
Operating Expenses 35.65 Cr33.32 Cr37.53 Cr37.51 Cr37.93 Cr
Operating Income 10.56 Cr14.27 Cr9.99 Cr10.69 Cr10.20 Cr
EBITDA 15.93 Cr19.13 Cr12.09 Cr16.04 Cr16.61 Cr
Interest Expense 5.90 Cr6.28 Cr5.15 Cr5.06 Cr4.25 Cr
Pretax Income 5.53 Cr8.15 Cr2.28 Cr6.30 Cr7.62 Cr
Tax Provision 1.25 Cr2.19 Cr1.07 Cr1.67 Cr2.09 Cr
Net Income 4.28 Cr5.96 Cr1.21 Cr4.63 Cr5.53 Cr
Diluted EPS 1.101.530.351.351.61

Profit & Loss (Annual)

Figures in INR.

Metric Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Revenue -257.53 Cr278.44 Cr274.71 Cr287.68 Cr
Cost of Revenue -105.51 Cr109.67 Cr94.06 Cr96.65 Cr
Gross Profit -152.02 Cr168.77 Cr180.65 Cr191.03 Cr
Operating Expenses -117.16 Cr130.46 Cr139.38 Cr149.90 Cr
Operating Income -34.86 Cr38.31 Cr41.27 Cr41.13 Cr
EBITDA -55.42 Cr57.52 Cr61.05 Cr60.60 Cr
Interest Expense -34.38 Cr32.40 Cr27.95 Cr20.75 Cr
Pretax Income -2.69 Cr5.39 Cr14.71 Cr21.12 Cr
Tax Provision -4.80 Cr1.76 Cr4.21 Cr6.25 Cr
Net Income --2.11 Cr3.63 Cr10.50 Cr14.88 Cr
Diluted EPS --0.540.942.704.33

Balance Sheet (Annual)

Figures in INR.

Metric Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Total Assets -374.06 Cr352.12 Cr381.76 Cr557.98 Cr
Current Assets -131.01 Cr117.89 Cr137.92 Cr238.53 Cr
Cash & Equivalents -11.11 L1.54 Cr22.06 L81.01 Cr
Inventory -68.92 Cr59.45 Cr72.98 Cr82.71 Cr
Receivables -53.58 Cr48.17 Cr50.08 Cr43.02 Cr
Total Liabilities -311.18 Cr285.83 Cr285.37 Cr337.77 Cr
Current Liabilities -97.13 Cr101.66 Cr115.08 Cr141.06 Cr
Long Term Debt -164.83 Cr138.01 Cr121.02 Cr161.97 Cr
Total Debt -214.00 Cr200.08 Cr192.60 Cr244.44 Cr
Total Equity -62.88 Cr66.29 Cr96.39 Cr220.21 Cr
Shares Outstanding -3.88 Cr3.88 Cr3.88 Cr3.88 Cr

Cash Flows (Annual)

Figures in INR.

Metric Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating Cash Flow -42.58 Cr58.07 Cr46.62 Cr48.45 Cr
Investing Cash Flow --6.53 Cr-10.32 Cr-24.47 Cr-93.61 Cr
Financing Cash Flow --42.32 Cr-46.32 Cr-23.47 Cr125.95 Cr
Capital Expenditure --6.29 Cr-13.41 Cr-20.77 Cr-80.19 Cr
Free Cash Flow -36.29 Cr44.66 Cr25.85 Cr-31.74 Cr
Net Change in Cash --6.27 Cr1.43 Cr-1.32 Cr80.79 Cr

Ratios (Annual)

Figures in %.

Metric Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Gross Margin % -59.0%60.6%65.8%66.4%
Operating Margin % -13.5%13.8%15.0%14.3%
Net Margin % --0.8%1.3%3.8%5.2%
ROE % --3.4%5.5%10.9%6.8%
ROCE % -12.6%15.3%15.5%9.9%

Shareholding Pattern

Insiders
68.50%
Institutions
6.92%
Public Float
21.96%

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for AMANTA

Google News Sat, 27 Jun 2026

AMANTA Stock Price and Chart — NSE:AMANTA - TradingView

<a href="https://news.google.com/rss/articles/CBMiW0FVX3lxTE5lV2VCSDJIdzdKNXJXdUN2UXQ3cTNTWHhlNDJ3RTY3S1Noem9KemJfZU54SWU0Z0JCMnhFTS1pM3pfTnVZRldxN0tZQ19zXzNCSFdaS2pkeWR4SEk?oc=5" target="_blank">AMANTA Stock Price and Chart — NSE:AMANTA</a…

Google News hu, 18 Jun 2026

Amanta Healthcare Co-Promoter Acquires 63 Lakh Shares Representing 16.3% Stake Via Open Market - Sahi

<a href="https://news.google.com/rss/articles/CBMizAFBVV95cUxNdk9vNVJHcjBYUFlia1c4cTRCNF9uZnhyeEszcy02ZmhlMUJmeDhHYzJKSVB0cnctVHprZnlfMWRSY0Y1VXVjY0lyVTRBRGFhS1BqdENlQV9KVmNmZ0w4R2gzeW94dWFTN0lxQ2I2NUotY0J3UDcwM0syY0hadk5scHV3bzdnLVE4R2k4N3…

Google News Wed, 01 Jul 2026

Amanta Healthcare discloses off-market share transfers worth ₹1,60,000 - scanx.trade

<a href="https://news.google.com/rss/articles/CBMixAFBVV95cUxORjNndVZmZ3g3X1ZWNmZ2OTFfaHhycE01RG9UU1VWdHd5WGFfUXRnUnI1QnhIRWN4Z2lVLUFhTUpYanVIeWxTNTZraEJYZGVFelhzMnNTaV9sMmY5VEFpVG54a0ZqRDZEeTdacl9QeVhFNzFLclE3bFBmdllGOFNTMVlqY1p3QnhnVDVra2…

Google News Wed, 20 May 2026

Amanta Health Standalone March 2026 Net Sales at Rs 76.99 crore, up 6.84% Y-o-Y - Moneycontrol.com

<a href="https://news.google.com/rss/articles/CBMi2wFBVV95cUxQblh0VUp5VEtRVUJQQVFmMUYxVXcta1dscnNMWi1seTFJNEM2a0cwX001WnBzR21fOGJwZEV5WmMzVGtTR1JYbG9uZkxPbXo3ekx4R1dGdy1lRU9KeHlNdEFaZjE2QzVuYXMxZlBFN1BNa2JGMTNkNVFnSFc1d3hpZWhHTDFvZnRPQ1R3Ym…

Google News Sat, 11 Jul 2026

Pakka - Unique Picks: 7 stocks held by a single MF scheme in June; rally up to 120% in 3 months - The Economic Times

<a href="https://news.google.com/rss/articles/CBMi9AFBVV95cUxOLVcwNThBV3d3dUpSV3YzeUNVUWxUbGFaQno2aDlPdl9uX3BfRmtsNzNQQ2IxZ29DNW9LTHFEWHlQZXg1M19pTmpqeWZYOEEyeUZDVUQ4b3hfbWpjM2ZjbnpYMkR0U2wwdUdKd3NaamlDVGUza2FRZVRfNzNXcXJsQ1hleHFmbWdocFdTU3…

Google News Mon, 29 Sep 2025

Amanta Healthcare lists at ₹135 on NSE, a 7% premium over IPO price - Groww

<a href="https://news.google.com/rss/articles/CBMihAFBVV95cUxPeEJEa1JHTzIyTkRqb05Yb19qdlR1Ui1MR0Jfa3QwR2xZRHd2SVFxVEtKR0pQM1JFODVlWkpacU0tN1dVUVVuWnUxZGJpdHE4anAtOFVIQ0w2NGRLUVJJbExKVEo3Y0R4RDFLc3RYb3FTb3ZjRDR5VUlsbjhQd1hiNmdzZk4?oc=5" targ…

AMANTA — Frequently Asked Questions

What is the current share price of AMANTA HEALTHCARE LIMITED (AMANTA)?

As of 2026-07-16 05:21 IST, AMANTA HEALTHCARE LIMITED (AMANTA) trades at ₹168.64 on NSE. Its 52-week range is ₹95.03 to ₹186.47.

What is the market capitalisation of AMANTA?

AMANTA HEALTHCARE LIMITED (AMANTA) has a market capitalisation of ₹654.82 Cr on NSE.

What is the P/E ratio of AMANTA?

AMANTA trades at a trailing price-to-earnings (P/E) ratio of 38.95. The industry average P/E is 39.70. Its price-to-book (P/B) ratio is 2.74.

What is the return on equity (ROE) of AMANTA?

AMANTA has a return on equity (ROE) of 6.75%. Its return on capital employed (ROCE) is 10.04%.

Is AMANTA a good stock to buy?

This page provides a data-driven analysis of AMANTA HEALTHCARE LIMITED (AMANTA), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All India Stocks
⚙Ad space